Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

By Kelly Bilodeau • March 17, 2025

Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

By Amy Baxter • March 17, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Lawmakers tease out pharma’s influence over RFK Jr. through probe into Mar-a-Lago meetings

HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

By Michael Gibney • March 13, 2025

Takeda’s $770M deal deepens Big Pharma’s omics push

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

By Alexandra Pecci • March 13, 2025

IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

By Amy Baxter • March 12, 2025

The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

By Amy Baxter • March 11, 2025

Pricing transparency is in the spotlight — and that could be good news for drugmakers

An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?

By Michael Gibney • March 11, 2025

What’s driving pharma’s layoffs in 2025

Familiar foes in the industry have claimed a slew of jobs in recent months.

By Meagan Parrish • March 10, 2025

As tariffs loom over pharma manufacturing, a reshoring effort is underway — but not without challenges

Experts say cost and other barriers present challenges to returning to U.S. shores.

By Kelly Bilodeau • March 10, 2025

The time is ripe for pharma M&A. Why are drugmakers holding out?

The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

By Michael Gibney • March 6, 2025

With patent losses on the horizon, Amgen refocuses its business strategy

The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

By Alexandra Pecci • March 5, 2025

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

By Jonathan Gardner • March 5, 2025

Americans want to participate in clinical trials — so why don’t they?

A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.

By Kelly Bilodeau • March 4, 2025

How pharma CEO pay shifted for these 4 companies last year

Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.

By Amy Baxter • March 3, 2025

Teva targets schizophrenia to build on innovative medicines growth

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

By Meagan Parrish • Feb. 28, 2025

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

By Michael Gibney • Feb. 27, 2025

Cancer vaccines have stumbled, but the approach is gaining new steam

The number of candidates in development has nearly doubled over the past 15 years.

By Kelly Bilodeau • Feb. 26, 2025

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

By Ned Pagliarulo • Feb. 25, 2025

Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

By Michael Gibney • Feb. 25, 2025

Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms

Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.

By Amy Baxter • Feb. 24, 2025

In FDA job cuts, experts see threat of far-reaching impact

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.

By Jonathan Gardner , Delilah Alvarado • Feb. 21, 2025

A look at Trump’s healthcare cuts — so far

How the federal workforce crackdown has impacted the agencies that oversee pharma and healthcare.

By Meagan Parrish • Feb. 21, 2025

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

By Michael Gibney • Feb. 20, 2025

Challenges mount for vaccine makers

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.

By Amy Baxter • Feb. 19, 2025

Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production

The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.

By Alexandra Pecci • Feb. 19, 2025